The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Longitudinal Links between Changes in Body Composition and Liver Disease Severity in Children and Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease
Objective: To investigate the relationship between longitudinal changes in body composition and liver disease severity in children with metabolic dysfunction-associated steatotic liver disease (MASLD).
Study design: This longitudinal, single-center, retrospective analysis included patients aged <20 years followed for MASLD who had had ≥2 bioelectrical impedance analyses (BIA) performed. MASLD regression was defined as alanine aminotransferase (ALT) normalization or reduction >50% from baseline. Fat and skeletal muscle mass were adjusted for size by calculating respective indices (dividing by height2). Logistic and linear regressions were used to determine the independent relationship between changes in body composition over time and serologic markers of liver disease severity.
Results: 258 patients (75% male, 50% Hispanic) were included with median age of 14 years (IQR: 11, 16) at the time of first BIA. Median body mass index (BMI) z-score at baseline was 2.33 (IQR: 2.04, 2.62). Median time from first to last BIA was 12 months (IQR: 6, 24). A decrease in fat mass index was independently associated with reductions in ALT and gamma glutamyl transferase (GGT) and increased odds of MASLD-regression (OR: 0.55, p<0.001). Fat mass index reduction was superior to BMI z-score in predicting MASLD-regression. Change in skeletal muscle mass index was not associated with change in ALT or GGT.
Conclusions: Changes in fat mass, not skeletal muscle mass, are associated with serologic markers of liver injury in youth with MASLD. Fat mass changes outperform BMI z-score changes in predicting MASLD regression. BIA can serve as an adjunct biomarker of liver disease progression.